See more : CXApp Inc. (CXAIW) Income Statement Analysis – Financial Results
Complete financial analysis of Concord Drugs Limited (CONCORD.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concord Drugs Limited, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Drinks Americas Holdings, Ltd. (DKAM) Income Statement Analysis – Financial Results
- Parkson Retail Group Limited (3368.HK) Income Statement Analysis – Financial Results
- ChainSea Information Integration Co.,Ltd. (6898.TWO) Income Statement Analysis – Financial Results
- Boardwalk Real Estate Investment Trust (BOWFF) Income Statement Analysis – Financial Results
- Immediate Acquisition Plc (IME.L) Income Statement Analysis – Financial Results
Concord Drugs Limited (CONCORD.BO)
About Concord Drugs Limited
Concord Drugs Ltd. engages in the provision of pharmaceutical formulations. Its products include ready to fill pellets, mup's tissue bio adhesive, injectables, oral solid dosages, oral solid dosages, and liquid orals. The company was founded on April 24, 1995 and is headquartered in Hyderabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 449.25M | 520.81M | 589.57M | 513.57M | 513.39M | 481.53M | 519.17M | 576.36M | 508.85M | 403.94M | 340.75M | 280.67M |
| Cost of Revenue | 332.54M | 410.30M | 421.37M | 430.72M | 427.02M | 399.79M | 435.24M | 464.24M | 390.44M | 314.21M | 294.80M | 246.79M |
| Gross Profit | 116.70M | 110.51M | 168.20M | 82.85M | 86.37M | 81.75M | 83.94M | 112.12M | 118.41M | 89.73M | 45.95M | 33.88M |
| Gross Profit Ratio | 25.98% | 21.22% | 28.53% | 16.13% | 16.82% | 16.98% | 16.17% | 19.45% | 23.27% | 22.21% | 13.48% | 12.07% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.69M | 2.06M | 2.27M | 2.33M | 1.70M | 25.29M | 19.74M | 28.07M | 16.14M | 6.16M | 10.66M | 9.20M |
| Selling & Marketing | 1.53M | 1.52M | 1.21M | 1.87M | 1.08M | 1.13M | 1.03M | 375.00K | 118.42K | 160.32K | 1.77M | 1.54M |
| SG&A | 3.22M | 3.58M | 3.48M | 4.20M | 2.78M | 26.43M | 20.77M | 28.44M | 16.26M | 6.32M | 12.43M | 10.74M |
| Other Expenses | 113.49M | 28.00K | 25.00K | 4.36K | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 116.70M | 79.96M | 76.60M | 62.87M | 67.57M | 61.71M | 59.80M | 83.84M | 63.53M | 52.56M | 24.40M | 18.29M |
| Cost & Expenses | 398.09M | 490.25M | 497.97M | 493.59M | 494.59M | 461.49M | 495.04M | 548.08M | 453.97M | 366.77M | 319.20M | 265.08M |
| Interest Income | 0.00 | 60.00K | 123.00K | 80.65K | 941.00K | 15.64M | 17.75M | 21.80M | 25.24M | 26.68M | 17.26M | 4.78M |
| Interest Expense | 18.68M | 17.28M | 16.77M | 13.31M | 14.46M | 15.71M | 17.82M | 24.25M | 25.25M | 26.68M | 17.81M | 0.00 |
| Depreciation & Amortization | 15.55M | 16.26M | 17.65M | 13.65M | 14.64M | 17.12M | 24.01M | 25.84M | 29.12M | 36.28M | 11.43M | 7.17M |
| EBITDA | 40.52M | 45.81M | 56.79M | 32.83M | 34.32M | 37.35M | 49.08M | 56.52M | 84.96M | 73.94M | 33.51M | 23.14M |
| EBITDA Ratio | 9.02% | 8.87% | 18.38% | 6.39% | 6.51% | 7.76% | 9.45% | 9.81% | 16.70% | 18.30% | 9.84% | 8.25% |
| Operating Income | 51.15M | 29.46M | 39.14M | 19.41M | 19.68M | 20.23M | 25.07M | 30.68M | 55.84M | 37.66M | 22.09M | 15.97M |
| Operating Income Ratio | 11.39% | 5.66% | 6.64% | 3.78% | 3.83% | 4.20% | 4.83% | 5.32% | 10.97% | 9.32% | 6.48% | 5.69% |
| Total Other Income/Expenses | -44.87M | -43.17M | -41.85M | 146.69K | -14.24M | -20.49M | -15.83M | -77.21M | -26.21M | -27.16M | -29.23M | -5.16M |
| Income Before Tax | 6.29M | 12.49M | 22.48M | 42.92M | 4.57M | 4.40M | 6.39M | 6.47M | 29.63M | 10.49M | 4.28M | 10.81M |
| Income Before Tax Ratio | 1.40% | 2.40% | 3.81% | 8.36% | 0.89% | 0.91% | 1.23% | 1.12% | 5.82% | 2.60% | 1.26% | 3.85% |
| Income Tax Expense | 1.57M | 2.63M | 6.54M | 10.10M | 1.28M | 328.00K | 3.15M | 4.88M | 12.15M | 3.53M | 896.90K | 400.84K |
| Net Income | 4.72M | 9.86M | 15.94M | 32.82M | 3.28M | 4.07M | 3.24M | 1.60M | 17.48M | 6.96M | 3.39M | 10.41M |
| Net Income Ratio | 1.05% | 1.89% | 2.70% | 6.39% | 0.64% | 0.85% | 0.62% | 0.28% | 3.44% | 1.72% | 0.99% | 3.71% |
| EPS | 0.47 | 1.06 | 1.82 | 3.75 | 0.38 | 0.52 | 0.41 | 0.22 | 2.41 | 0.96 | 0.47 | 1.44 |
| EPS Diluted | 0.47 | 1.06 | 1.82 | 3.75 | 0.38 | 0.52 | 0.41 | 0.22 | 2.41 | 0.96 | 0.47 | 1.44 |
| Weighted Avg Shares Out | 10.05M | 9.32M | 8.74M | 8.74M | 8.74M | 7.86M | 7.90M | 7.25M | 7.26M | 7.25M | 7.24M | 7.24M |
| Weighted Avg Shares Out (Dil) | 10.05M | 9.32M | 8.74M | 8.74M | 8.74M | 7.86M | 7.86M | 7.24M | 7.24M | 7.24M | 7.24M | 7.24M |
Source: https://incomestatements.info
Category: Stock Reports